Why do people compare CJC-1295 to tesamorelin?

Both are changed versions of growth hormone releasing hormone, and both act on the same docking spot on the pituitary gland. That is the whole reason for the comparison. The real difference is approval and evidence. Tesamorelin is FDA approved as Egrifta, with a study program of more than 800 people for one specific use. CJC-1295 has never been approved anywhere and has only two studies in people in this site's review. So the two molecules are closer than the evidence behind each one.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of growth hormone secretagogues. Sermorelin, tesamorelin, ipamorelin, CJC-1295, and the rest of the GHRH and ghrelin receptor family.